GL Pharm Tech Statistics

Total Valuation

GL Pharm Tech has a market cap or net worth of KRW 98.82 billion. The enterprise value is 111.60 billion.

Market Cap	98.82B
Enterprise Value	111.60B

Important Dates

The last earnings date was Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

GL Pharm Tech has 76.97 million shares outstanding. The number of shares has increased by 20.47% in one year.

Current Share Class	76.97M
Shares Outstanding	76.97M
Shares Change (YoY)	+20.47%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.18%
Owned by Institutions (%)	n/a
Float	48.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.52
PB Ratio	5.02
P/TBV Ratio	5.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 73.60, with an EV/FCF ratio of -24.25.

EV / Earnings	-163.92
EV / Sales	3.98
EV / EBITDA	73.60
EV / EBIT	n/a
EV / FCF	-24.25

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.97.

Current Ratio	1.47
Quick Ratio	0.82
Debt / Equity	0.97
Debt / EBITDA	12.85
Debt / FCF	-4.17
Interest Coverage	-0.26

Financial Efficiency

Return on equity (ROE) is -3.40% and return on invested capital (ROIC) is -0.29%.

Return on Equity (ROE)	-3.40%
Return on Assets (ROA)	-0.24%
Return on Invested Capital (ROIC)	-0.29%
Return on Capital Employed (ROCE)	-0.58%
Revenue Per Employee	1.04B
Profits Per Employee	-25.21M
Employee Count	27
Asset Turnover	0.61
Inventory Turnover	1.96

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.09% in the last 52 weeks. The beta is 1.01, so GL Pharm Tech's price volatility has been similar to the market average.

Beta (5Y)	1.01
52-Week Price Change	+7.09%
50-Day Moving Average	1,160.64
200-Day Moving Average	1,064.26
Relative Strength Index (RSI)	56.13
Average Volume (20 Days)	529,838

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GL Pharm Tech had revenue of KRW 28.05 billion and -680.77 million in losses. Loss per share was -8.85.

Revenue	28.05B
Gross Profit	11.80B
Operating Income	-177.95M
Pretax Income	-675.34M
Net Income	-680.77M
EBITDA	1.49B
EBIT	-177.95M
Loss Per Share	-8.85

Full Income Statement

Balance Sheet

The company has 6.39 billion in cash and 19.17 billion in debt, giving a net cash position of -12.77 billion or -165.94 per share.

Cash & Cash Equivalents	6.39B
Total Debt	19.17B
Net Cash	-12.77B
Net Cash Per Share	-165.94
Equity (Book Value)	19.69B
Book Value Per Share	255.86
Working Capital	6.96B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.11 billion and capital expenditures -488.11 million, giving a free cash flow of -4.60 billion.

Operating Cash Flow	-4.11B
Capital Expenditures	-488.11M
Free Cash Flow	-4.60B
FCF Per Share	-59.78

Full Cash Flow Statement

Margins

Gross margin is 42.08%, with operating and profit margins of -0.63% and -2.43%.

Gross Margin	42.08%
Operating Margin	-0.63%
Pretax Margin	-2.41%
Profit Margin	-2.43%
EBITDA Margin	5.32%
EBIT Margin	-0.63%
FCF Margin	n/a

Dividends & Yields

GL Pharm Tech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.47%
Shareholder Yield	n/a
Earnings Yield	-0.69%
FCF Yield	-4.66%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GL Pharm Tech has an Altman Z-Score of 2.04. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.04
Piotroski F-Score	n/a